transparency and pharmaceutical practice from a meta country
DESCRIPTION
Presentation by Normita D. Leyesa, President, Philippine Pharmacists Association on Transparency and Pharmaceutical Practice from a MeTA Country during the 69th FIP Congress, Istanbul, September 2009.TRANSCRIPT
FIP-WHO META Istanbul, Turkey September 5, 2009 1
Normita D. Leyesa, RPh, MS
President, Philippine Pharmacists Association
MeTA Council Member
Transparency and Pharmaceutical Transparency and Pharmaceutical Practice from a MeTA Country:Practice from a MeTA Country:
The MeTA Philippines Country ReportThe MeTA Philippines Country Report
1
FIP-WHO META Istanbul, Turkey September 5, 2009 2
Medicine Transparency Alliance Medicine Transparency Alliance (MeTA) initiative proposes to (MeTA) initiative proposes to improve accessimprove access to medicines to medicines through through transparencytransparency and and accountabilityaccountability..
FIP-WHO META Istanbul, Turkey September 5, 2009 33
The Philippines Work The Philippines Work Plan for the Phase I Plan for the Phase I 2009-20102009-2010
Objective:Objective:
Provide adequate information that would strengthen decision-making and implementation of processes along the medicines registration, selection, procurement, and use.
FIP-WHO META Istanbul, Turkey September 5, 2009 4
Preparation of Preparation of the Work Planthe Work Plan
Identification of priority areas for MeTA Identification of priority areas for MeTA intervention by scoping visits, consultations, and intervention by scoping visits, consultations, and stakeholder mapping stakeholder mapping
Identification of areas supported by other Identification of areas supported by other international development partners and international development partners and stakeholdersstakeholders
Line-up of activities and allocated budget were Line-up of activities and allocated budget were finally deliberated and approvedfinally deliberated and approved
FIP-WHO META Istanbul, Turkey September 5, 2009 5
Three Key Points Three Key Points of of Phase IPhase I
1.1. Country structure and commitmentCountry structure and commitment
2.2. Transparency: disclosure, data collection Transparency: disclosure, data collection and analysisand analysis
3.3. Accountability: multi-stakeholder Accountability: multi-stakeholder approach and good governanceapproach and good governance
FIP-WHO META Istanbul, Turkey September 5, 2009 6
2009-2010 2009-2010 Strategic Work PlanStrategic Work Plan
Developing Information on Prices, Availability, Developing Information on Prices, Availability, Financing Mechanisms and Rational Drug UseFinancing Mechanisms and Rational Drug Use
Generating Information to Improve Quality of Generating Information to Improve Quality of PharmaceuticalsPharmaceuticals
Setting up Systems for Transparency in Medicines Setting up Systems for Transparency in Medicines Registration, Selection, Procurement and UsageRegistration, Selection, Procurement and Usage
Supporting Transparency Agenda in Decentralized Supporting Transparency Agenda in Decentralized SystemsSystems
Preparation of Budget for the Activities Preparation of Budget for the Activities
FIP-WHO META Istanbul, Turkey September 5, 2009 7
KEY OUTCOMESKEY OUTCOMES
FIP-WHO META Istanbul, Turkey September 5, 2009 8
Key Outcome 1:Key Outcome 1: Available information on Available information on medicines quality, registration, medicines quality, registration, access, promotions, and rational access, promotions, and rational drug usedrug use
Analysis of existing pharmaceutical data (ongoing)Analysis of existing pharmaceutical data (ongoing) Conduct of Level II and III Survey on medicines Conduct of Level II and III Survey on medicines
(ongoing)(ongoing) Assessment of Public Sector Assessment of Public Sector
– Procurement (including PITC) of medicinesProcurement (including PITC) of medicines– Design of Design of ee-procurement system-procurement system– Assessment of the current systems for financing Assessment of the current systems for financing
medicines for the poor (TOR)medicines for the poor (TOR) Survey of quality of medicines using the “FDA in a Survey of quality of medicines using the “FDA in a
suitcase” suitcase” Study on medicines promotion and advertisement Study on medicines promotion and advertisement
(TOR)(TOR)
FIP-WHO META Istanbul, Turkey September 5, 2009 9
Key Outcome 2:Key Outcome 2: Setting up of information Setting up of information structures and systemsstructures and systems
Improvement of the medicines registrationImprovement of the medicines registration
FDA websiteFDA website
Philippine National Drug Formulary Website Philippine National Drug Formulary Website
Support to the implementation of the Electronic Support to the implementation of the Electronic Essential Drug Price Monitoring System (E-EDPMS) at Essential Drug Price Monitoring System (E-EDPMS) at the regional and provincial levelsthe regional and provincial levels
Development of systems for monitoring and Development of systems for monitoring and evaluation of ethical practices of industry and the evaluation of ethical practices of industry and the medical professionmedical profession
Development and testing of monitoring tools for Development and testing of monitoring tools for prescription auditsprescription audits
FIP-WHO META Istanbul, Turkey September 5, 2009 10
Key Outcome 3:Key Outcome 3: Improvement of technical Improvement of technical capacity for disclosure, analysis, and capacity for disclosure, analysis, and the use of information and evidencethe use of information and evidence
Pharmaceutical Management and Good Governance Pharmaceutical Management and Good Governance Course for LGU Health Managers and Local Chief Course for LGU Health Managers and Local Chief ExecutivesExecutives
National Good Governance in Medicines AwardsNational Good Governance in Medicines Awards
Strengthening of Drug Therapeutic Committees (DTC) at Strengthening of Drug Therapeutic Committees (DTC) at Regional and Provincial levelsRegional and Provincial levels
Technical capacity building for DTCsTechnical capacity building for DTCs
Development of tools for monitoring/evaluation of DTCsDevelopment of tools for monitoring/evaluation of DTCs
Piloting of the Pharmaceutical Bench BookPiloting of the Pharmaceutical Bench Book
FIP-WHO META Istanbul, Turkey September 5, 2009 11
Key Outcome 4:Key Outcome 4:Setting up mechanism for Setting up mechanism for advocacy and participation in advocacy and participation in decision making processesdecision making processes
MeTA Roundtable discussionsMeTA Roundtable discussions PublicationsPublications
– Development of the MeTA WebsiteDevelopment of the MeTA Website – Publication of Proceedings for MeTA ForumPublication of Proceedings for MeTA Forum– Publication of Baseline AssessmentsPublication of Baseline Assessments
Annual MeTA ForumAnnual MeTA Forum
FIP-WHO META Istanbul, Turkey September 5, 2009 12
Key Outcome 5:Key Outcome 5: Sustaining a Multi-stakeholder Sustaining a Multi-stakeholder CollaborationCollaboration
MeTA Council and Secretariat OperationsMeTA Council and Secretariat Operations Support to Civil Society OrganizationsSupport to Civil Society Organizations
– Coalition for Health Advocacy and TransparencyCoalition for Health Advocacy and Transparency
FIP-WHO META Istanbul, Turkey September 5, 2009 13
““The challenges in transparency and The challenges in transparency and accountability on medicine registration, accountability on medicine registration, selection, procurement, and use in the selection, procurement, and use in the Philippines are enormous. Philippines are enormous.
These can be summed up into two: These can be summed up into two: non-non-accessibility of data accessibility of data to policy, decision to policy, decision makers, and consumers and the makers, and consumers and the lack of lack of tools and structures tools and structures for adequate for adequate reporting, disclosure and feedback.”reporting, disclosure and feedback.”
FIP-WHO META Istanbul, Turkey September 5, 2009 14
With the assistance of MeTA With the assistance of MeTA International, and the Department of International, and the Department of International Development (DFID) UK, International Development (DFID) UK, and the support of the World Health and the support of the World Health Organization, we will be able to Organization, we will be able to surmount these challenges and surmount these challenges and ultimately, improve the healthcare ultimately, improve the healthcare delivery system in the Philippines for delivery system in the Philippines for the benefit of the Filipino people.the benefit of the Filipino people.
FIP-WHO META Istanbul, Turkey September 5, 2009 15
Thank You!Thank You!